Exchange: NASDAQ·Updated 07:30 PM EST

VSTM News

News
all
press releases
Verastem (NASDAQ:VSTM) Rating Lowered to Strong Sell at Wall Street Zen
Wall Street Zen downgraded shares of Verastem from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat
Verastem (NASDAQ:VSTM) Rating Lowered to Strong Sell at Wall Street Zen
Wall Street Zen downgraded shares of Verastem from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat
More News
Verastem (NASDAQ:VSTM) Stock Price Down 7.8% - Here's Why...
MarketBeat
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that a late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated...
Business Wire
Verastem (NASDAQ:VSTM) is preparing a broad development program for its experimental cancer drug VS-7375, with incoming CEO Michael Bailey saying the company is considering both partnerships and a potential independent launch as it awaits midstage trial results. At an investor discussion hosted by...
MarketBeat
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Verastem (VSTM) delivered earnings and revenue surprises of -68.18% and -15.60%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business progress. During the third quarter...
Business Wire
Clene (CLNN) delivered earnings and revenue surprises of +110.87% and -37.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to present at the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation...
Business Wire
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.